



SATURDAY, DECEMBER 9, 2017

**7:30 AM-9:00 AM**

**631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: Novel Targets and CML Stem Cell Biology**

***Saturday, December 9, 2017: 7:30 AM-9:00 AM  
Bldg B, Lvl 5, Murphy BR 3-4 (Georgia World Congress Center)***

**Program:** Oral and Poster Abstracts. Type: Oral

**Hematology Disease Topics & Pathways:** Diseases, Adult, CML, Therapies, Non-Biological, Mechanisms, Technology and Procedures, cytogenetics, Study Population, genomics, Clinically relevant, Myeloid Malignancies, hematopoiesis, Xenograft models, pharmacology, signal transduction

**Moderators:** Mhairi Copland, PhD, MBBChir, FRCP, FRCPATH, Gartnavel General Hospital and Michael W. Deininger, MD, PhD, Huntsman Cancer Institute, University of Utah

7:30h: 42 Inhibition of Nucleocytoplasmic Export Enhances Selective Elimination of Leukemic Stem Cells in Chronic Myeloid Leukemia, *Hein Than, MD, FRCPATH, MRCP*

7:45h: 43 SETD2 Loss of Function Is a Recurrent Event in Advanced-Phase Chronic Myeloid Leukemia, *Manuela Mancini, PhD*

8:00h: 44 De Novo UBE2A Mutations Are Recurrently Acquired during CML Progression and Interfere with Myeloid Differentiation Pathways, *Mario Mauri, PhD*

8:15h: 45 The Bone Marrow Niche Uses Mir-300 As a Biological Rheostat to Selectively Control Stem Cell-Driven Malignant Hematopoiesis and Innate Anti-Cancer Immunity, *Danilo Perrotti, MD, PhD*

8:30h: 46 Regulation of Asymmetric Division in Myeloid Leukemogenesis, *Jeevisha Bajaj, PhD*

8:45h: 47 Clinical and Molecular Characterization of Clonal Chromosomal Abnormalities Appearing in Philadelphia-Negative Metaphases of Chronic Phase CML, *Ghayas C. Issa, MD*



CML Advocates Network

SATURDAY, DECEMBER 9, 2017

---

**11:15AM – 12:15 AM**

CARER DEVELOPMENT LUNCH SESSIONS

**Treating and Monitoring Patients With CML**

How I Treat: Bringing Science to Clinical Dilemmas

***Saturday, December 9, 2017: 11:15 AM-12:15 PM***

***Magnolia, No. Twr, M2 (Omni Hotel at CNN Center)***

Speaker: Francois-Xavier Mahon, MD, PhD, Bordeaux Segalen University



SATURDAY, DECEMBER 9, 2017

---

**2:00PM-3:30PM**

**Chronic Myeloid Leukemia: Where Are We in the Current TKI Era?  
Education Program**

***Saturday, December 9, 2017: 7:30 AM-9:00 AM***

***Bldg C, Lvl 1, Hall C1 (Georgia World Congress Center)***

***Saturday, December 9, 2017: 2:00 PM-3:30 PM***

***Bldg B, Lvl 3, B312-B314 (Georgia World Congress Center)***

Chair: Francois-Xavier Mahon, MD, PhD, Bordeaux Segalen University

Description:

The survival rate for patients with chronic myeloid leukemia (CML) who are treated with tyrosine kinase inhibitors (TKI) is now similar to that of the healthy population. However, recent reports of adverse events in patients who received TKI treatment have raised concerns about long-term sequelae of drugs that have been administered for decades. Improving the management of TKI-related adverse events and increasing the number of patients eligible for treatment-free remission will be essential to improving patients' quality of life.

Treatment-Free Remission: Who, How, and Why?

Dr. François-Xavier Mahon will review and summarize the recent studies related to TKI cessation in patients with deep molecular response, which have raised the idea of treatment-free remission. He will also discuss the awareness of CML curability.

TKI-Associated Cardiovascular Toxicity: What to Consider

Dr. Javid Moslehi will discuss the side effects of BCR-ABL1 TKI, focusing on cardiovascular toxicity. He will review what is currently known about the cardiovascular toxicities of TKI and discuss potential mechanisms underlying cardiovascular adverse events. Dr. Moslehi will provide the practical progress and recommendations for using TKI, illustrating the essential cooperation between hematologists and cardiologists.

Novel Approaches to Therapy in CML

Dr. Ravi Bhatia will review the concept of TKI resistance, focusing on leukemic stem cells. He will discuss new therapies for CML, with the goal of increasing the rate of treatment-free remission candidates. Dr. Bhatia will explain how to better target the leukemic stem cells and will review the current clinical trials which attempt to eliminate them.



SATURDAY, DECEMBER 9, 2017

---

**4:00 PM-5:30 PM**

**632. Chronic Myeloid Leukemia: Therapy: NGS-based and Mechanistic Studies**

***Saturday, December 9, 2017: 4:00 PM-5:30 PM***

***Bldg B, Lvl 2, B206 (Georgia World Congress Center)***

Program: Oral and Poster Abstracts Type: Oral

Hematology Disease Topics & Pathways: Biological, Diseases, Therapies, CML, Mechanisms, Technology and Procedures, Myeloid Malignancies, TKI, NGS, multi-systemic interactions

Moderators: Fausto Castagnetti, MD, PhD, Bologna University School of Medicine and Dong-Wook Kim, MD, PhD, Seoul St. Mary's Hospital The Catholic University of Korea

4:00 PM **247** Cytogenetics-Based Risk Prediction of Blastic Transformation of CML Treated with Tyrosine Kinase Inhibitors, *Zimu Gong, MD*

4:15 PM **248** What's Next in CML – a Prospective Study Evaluating Sanger Sequencing and Next Generation Sequencing (NGS) for BCR-ABL1 Kinase Domain (KD) Mutation Screening, *Simona Soverini, PhD*

4:30 PM **249** Persistence of Residual Circulating CD26+ Leukemia Stem Cells in Chronic Myeloid Leukemia Patients in Treatment Free Remission, *Monica Bocchia, MD*

4:45 PM **250** Identification of Progression-Associated Mutations in Chronic Myeloid Leukemia (CML) By Comparative Genomic Analysis, *Shady Adnan Awad, MD*

5:00 PM **251** Integrative Genomics Reveals Cancer Associated Mutations Are Common at Diagnosis of CML in Patients with Poor Response to TKI Therapy, *Susan Branford, PhD*

5:15 PM **252** Incidence of Low Level Mutations in Newly Diagnosed CML Patients: A Substudy of the German Tiger Trial, *Georg-Nikolaus Franke, MD*



SUNDAY, DECEMBER 10, 2017

**7:30 AM-9:00 AM**

**632. Chronic Myeloid Leukemia: Therapy: Treatment Discontinuation, Dose Reduction, and Prognostic Indicators**

***Sunday, December 10, 2017: 7:30 AM-9:00 AM  
Bldg A, Lvl 4, Marcus Aud. (Georgia World Congress Center)***

Program: Oral and Poster Abstracts

Type: Oral

Hematology Disease Topics & Pathways:

Adult, Biological, Diseases, Therapies, CML, Pediatric, Study Population, Clinically relevant, Myeloid Malignancies, TKI

Moderators:

Sarit Assouline, MD, McGill University Jewish General Hospital and Susanne Saussele, MD, University of Heidelberg

**7:30 AM 313 "Duration of Deep Molecular Response" Has Most Impact on the Success of Cessation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia - Results from the EURO-SKI Trial** ***Susanne Saussele, MD***

**7:45 AM 314 Dasatinib Discontinuation in Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) and Stable Deep Molecular Response (DASFREE)** ***Neil P. Shah, MD, PhD***

**8:00 AM 315 Persistence with Generic Imatinib for Chronic Myeloid Leukemia: A Matched Cohort Study** ***Adi J. Kiiil-Drori, MD***

**8:15 AM 316 Advanced Phases at Diagnosis of Childhood Chronic Myeloid Leukemia : The Experience of the International Registry for Chronic Myeloid Leukemia (CML) in Children and Adolescents (I-CML-Ped Study)** ***Frédéric Millot***

**8:30 AM 317 Deeper Molecular Response in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 36 Months Follow-up** ***Young Rok Do, MD, PhD***

**8:45 AM 318 Molecular Responses after Switching from a Standard-Dose Twice-Daily Nilotinib Regimen to a Reduced-Dose Once-Daily Schedule in Patients with Chronic Myeloid Leukemia: A Real Life Observational Study (NILO-RED)** ***Delphine Rea, MD***



MONDAY, DECEMBER 11, 2017

---

**6:15 PM-7:45 PM**

**632. Chronic Myeloid Leukemia: Therapy: Results of Clinical Trials**

***Monday, December 11, 2017: 6:15 PM-7:45 PM***

***Bldg C, Lvl 2, C202-C204 (Georgia World Congress Center)***

Program: Oral and Poster Abstracts Type: Oral  
Hematology Disease Topics & Pathways: Adult, Biological, Diseases, Therapies, CML, Pediatric, Study Population, Clinically relevant, Myeloid Malignancies, TKI

Moderators: Carlo Gambacorti-Passerini, MD, University of Milano Bicocca and Thomas Ernst, MD, Jena University Hospital

6:15 PM **895** PF-114 Mesylate, a Novel Third Generation ATP-Competitive BCR-ABL Tyrosine Kinase Inhibitor: First Safety and Efficacy Data from a Phase I Study in Patients with CML with Failure of Prior TKI Therapy ***Anna G Turkina, Prof., MD***

6:30 PM **896** Bosutinib Vs Imatinib for Newly Diagnosed Chronic Myeloid Leukemia (CML) in the BFORE Trial: 18 Month Follow-up ***Carlo Gambacorti-Passerini, MD***

6:45 PM **897** Final Evaluation of Randomized CML-Study IV: 10-Year Survival and Evolution of Terminal Phase Rüdiger Hehlmann, MD1

7:00 PM **898** Response to Front-Line Imatinib Treatment in Children and Adolescents with CML – Data from a Large Pediatric Cohort ***Meinolf Suttorp, MD, PhD***

7:15 PM **899** Nilotinib Versus Nilotinib Combined to Pegylated-Interferon Alfa 2a in First-Line Chronic Phase Chronic Myelogenous Leukemia Patients. Interim Analysis of a Phase III Trial ***Franck Emmanuel Nicolini, MD, PhD***

7:30 PM **900** Second-Line Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia (CP CML) Resistant or Intolerant to Prior Imatinib: An 8-Year Update ***Tim H. Brümmendorf, MD***